SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Opendoor Technologies, Inc. engages in the operation of buying, selling, and trading of residential properties online. The company was founded by Eric Wu on December 30, 2013, and is headquartered in Tempe, AZ.

Opendoor Technologies Inc

Opendoor Technologies is seeing intense community speculation as investors position themselves ahead of the upcoming earnings release, with discussions centering on the company's progress under new leadership and potential for a breakout. Enthusiastic retail participants are debating the impact of strategic housing market initiatives and tracking sentiment against bearish short-interest concerns.

Snap, Inc. is a technology company, which engages in the provision of a visual messaging application that was created to help people communicate through short videos and images. The company was founded by Frank Reginald Brown IV, Evan Thomas Spiegel, and Robert C. Murphy in 2010 and is headquartered in Santa Monica, CA.

Snap Inc - Ordinary Shares - Class A

Snap Inc

Snap is trending due to heightened community anticipation ahead of its upcoming earnings report, with investors weighing concerns over North American user growth against a growing narrative of improved operational efficiency and potential AI-driven monetization. Discussions are polarized, as some shareholders focus on long-term turnaround potential through cost-cutting and hardware innovation, while others remain critical of management and historical performance.

Arm Holdings Plc engages in the licensing, marketing, research, and development of microprocessors, systems IP, graphics processing units, physical IP and associated systems IP, software, and tools. It operates through the following geographical segments: United Kingdom, United States, and Other Countries. The company was founded on November 12, 1990 and is headquartered in Cambridge, the United Kingdom.

Arm Holdings plc. - ADR

Arm Holdings Plc.

Arm Holdings is currently in the spotlight as investors weigh its aggressive expansion into the data center CPU market against concerns over supply constraints and high valuation. While the community remains divided over the sustainability of its rapid growth, there is significant active discussion regarding its shift toward becoming a cornerstone of AI infrastructure.

Axe Compute, Inc. engages in the provision of graphics processing unit compute capacity for artificial intelligence and other complex computing workloads. It operates through the following segments: Compute Services and Treasury Management segment, and Drug Discovery Services segment. The Compute Services and Treasury Management segment provides services that include access to GPU compute capacity and manage the ATH Treasury Strategy. The Drug Discovery Services segment provides services that include the application of AI, creation of specific 3D culture models used in drug development. The company was founded by Lawrence W. Gadbaw, Peter L. Morawetz, and Jeffrey K. Drogue on April 23, 2002 and is headquartered in Pittsburgh, PA.

Axe Compute Inc.

Axe Compute Inc. Common Stock

Axe Compute Inc. is trending following the announcement of a significant multi-year enterprise contract to deploy Nvidia hardware, fueling community speculation about the company's valuation and revenue potential. While some investors are bullish on the AI infrastructure narrative and recent insider activity, others are actively debating potential dilution risks and the stock's high volatility.

Celsius Holdings, Inc. engages in the development, marketing, sale, and distribution of functional drinks and liquid supplements. It also offers post-workout functional energy drinks and protein bars. The company was founded in April 2004 and is headquartered in Boca Raton, FL.

Celsius Holdings Inc

Celsius Holdings is experiencing heightened investor debate as the stock faces downward pressure near 52-week lows, fueling community speculation about institutional manipulation versus legitimate concerns over competitive headwinds and integration noise. Investors are closely monitoring the upcoming earnings announcement for signs of a turnaround, with bullish sentiment anchored by long-term growth prospects, strong brand loyalty, and the potential for a post-earnings recovery.

ADMA Biologics, Inc. operates as a biopharmaceutical company, which is engaged in manufacturing, marketing, and developing specialty plasma-derived biologics. The firm operates through the following business segments: ADMA BioManufacturing and Plasma Collection Center. The ADMA BioManufacturing segment consists of immune globulin manufacturing and development operations. The Plasma Collection Center consists of source plasma collection facilities. The company was founded by Adam S. Grossman and Jerrold B. Grossman on June 24, 2004 and is headquartered in Ramsey, NJ.

Adma Biologics Inc

Adma Biologics is currently the center of intense debate following a short-seller report that triggered a sharp selloff, despite the company's aggressive rebuttal and a massive share buyback program. Investors are actively split between those who view the current price as a generational buying opportunity based on strong ASCENIV demand and pending label expansions, and those who remain skeptical due to the withdrawal of long-term guidance and ongoing competitive headwinds.

Immix Biopharma, Inc. operates as a biopharmaceutical company that engages in the development of therapies for cancer and inflammatory diseases. The company was founded by Ilya Rachman, Sean Senn, and Vladimir Torchilin in 2012 and is headquartered in Los Angeles, CA.

Immix Biopharma Inc

Immix Biopharma is seeing intense investor focus as community members anticipate near-term trial enrollment completion and regulatory progress toward a BLA submission for its NXC-201 therapy. The conversation is currently dominated by discussions around the potential for a strategic buyout or short squeeze, fueled by the stock's tight float, significant institutional accumulation, and the high-conviction clinical data in AL amyloidosis.

Ernexa Therapeutics, Inc. engages in the provision of cell engineering therapies. It is involved in the development of mRNA cell engineering technologies to repair cellular dysfunction and treat a range of therapeutic indications. The company was founded in 1984 and is headquartered in Cambridge, MA.

Ernexa Therapeutics Inc.

Ernexa Therapeutics is trending as the community debates the validity of recent preclinical data showing complete tumor clearance in ovarian cancer models against concerns regarding share dilution and historical reverse splits. Investors are actively split between those betting on the company's clinical pipeline and institutional partnerships as a catalyst for a short squeeze, and those warning of a potential 'dilution trap' following the latest volatility.

Root, Inc. is a technology insurance company, which engages in the provision of insurance services. It offers mobile telematics and technology platforms to segment individual risk based on complex behavioral data and customer experience to make pricing decisions and grow businesses. It provides insurance products and services in the United States. The company was founded by Alexander E. Timm and Daniel Manges in February 2015 and is headquartered in Columbus, OH.

Root Inc - Ordinary Shares - Class A

Root Inc

Root Inc. is trending as investors weigh strong profitability gains against slowing policy growth and reduced marketing spend. Community sentiment is deeply polarized, with bulls highlighting the potential of the Carvana partnership and share buyback program, while skeptics point to insider selling and concerns over the long-term sustainability of the current growth model.

Digi Power X, Inc. is a block chain technology company, which engages in crypto currency mining. It focuses on validation through mining, hosting solutions, and blockchain software solutions. It operates through the following segments: Cryptocurrency Mining, Sales of Energy and Electricity, and Colocation Services. The company was founded on February 18, 2017, and is headquartered in Miami, FL.

Digi Power X Inc. - Ordinary Shares (Sub voting)

Digi Power X is gaining significant traction following a major multi-year data center agreement with AI chip maker Cerebras Systems. Investors are actively discussing the stock's significant valuation gap compared to AI infrastructure peers and the potential for further upside as the market prices in the massive contract value and upcoming industry milestones.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Vanguard Announces Share Splits for Five Equity Index ETFs

Vanguard Announces Share Splits for Five Equity Index ETFs Vanguard Announces Share Splits for Five Equity Index ETFs PR Newswire VALLEY FORGE, Pa., March 24, 2026 VALLEY FORGE, Pa., March 24, 2026...

Should Vanguard S&P 500 Growth Index Fund ETF Shares (VOOG) Be on Your Investing Radar?

<ul class="summary-bullets"><li>Patients treated with povetacicept also demonstrated a 77.4% reduction from baseline in serum galactose deficient IgA1, a critical, disease-specific biomarker for IgA nephropathy, the company added.</li><li>Vertex now expects to complete necessary submissions seeking approval for povetacicept in IgA Nephropathy by March.</li><li>The company has a priority review voucher which would allow it to reduce the review time from ten months to six, it added.</li></ul><p><br>Shares of Vertex Pharmaceuticals Incorporated (VRTX) rose as much as 7% after hours on Monday after the company announced positive 36-week data from its ongoing late-stage trial evaluating povetacicept in immunoglobulin A nephropathy.</p><p>IgA nephropathy or Berger’s disease is an autoimmune kidney disease occurring when immunoglobulin A (IgA) antibody clumps deposit in the kidney’s glomeruli, causing inflammation and damage.</p><h2 class="st-heading-2">Trial Takeaways</h2><p>The company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://investors.vrtx.com/news-releases/news-release-details/vertex-announces-positive-week-36-interim-analysis-results">said</a> that patients treated with povetacicept on top of standard of care achieved a 52% reduction from baseline in urine protein to creatinine ratio at week 36, meeting the study’s key goal. The reduction was consistent across subgroups, the company said. &nbsp;</p><p>Patients treated with povetacicept also demonstrated a 77.4% reduction from baseline in serum galactose deficient IgA1, a critical, disease-specific biomarker for IgA nephropathy, the company added.</p><p>Povetacicept was generally safe and well tolerated with a majority of adverse events (AEs) being mild to moderate. There were no serious adverse events or deaths, and no discontinuations due to infections, the company added.</p><h2 class="st-heading-2">Plans Ahead</h2><p>Vertex now expects to complete necessary submissions seeking approval for povetacicept in IgA Nephropathy by March. The company has a priority review voucher which would allow it to reduce the review time from ten months to six, it added.</p><p>If approved, the company expects to launch povetacicept in a low volume subcutaneous auto-injector delivered once every four weeks via at-home administration.</p><p>Other companies with FDA-approved drugs for IgA Nephropathy include Travere Therapeutics and Novartis.</p><h2 class="st-heading-2">How Did Stocktwits Users React?</h2><p>On Stocktwits, retail sentiment around VRTX shares stayed within the ‘bearish’ territory over the past 24 hours, while message volume rose from ‘low’ to ‘normal’ levels.</p><p><a href="https://stocktwits.com/symbol/VRTX">VRTX stock</a> has declined 8% over the past 12 months.&nbsp;</p><p>Read More: <a href="https://stocktwits.com/news-articles/markets/equity/voyg-shares-decline-on-double-q4-miss-despite-record-2025-backlog/cZdVUXLRIeI">VOYG Shares Decline On Double Q4 Miss Despite Record 2025 Backlog</a></p><p><i>For updates and corrections, email newsroom[at]stocktwits[dot]com.</i></p>

In this photo illustration, Vertex Pharmaceuticals' logo is displayed on a smartphone screen in front of a stock chart. (Photo illustration by Cheng Xin/Getty Images)

VRTX Soars In Extended Hours After Experimental Drug Shows Positive Changes In Autoimmune Kidney Disease

The company said that patients treated with povetacicept achieved a 52.0% reduction from baseline in urine protein to creatinine ratio at week 36, meeting the study’s key goal.

Equity

Should Vanguard S&P 500 Growth ETF (VOOG) Be on Your Investing Radar?

Growth ETF (VOOG) Hits New 52-Week High

VOOG hits a 52-week high amid tech-driven momentum and optimism over Fed rate cuts, hinting at more upside ahead.

Less-Than-Expected Inflation in July: Growth ETFs to Gain?

CPI rose less than expected, boosting hopes for Fed rate cuts and sparking interest in top growth-focused ETFs like VUG and RPG.



Three Rate Cuts Expected in 2025? ETFs in Focus 

Fed officials signal possible rate cuts this year, boosting the appeal of growth-focused ETFs amid slowing labor market trends. Tap ETFs like VUG, RPG and VOOG.

Fed to Cut Rates Ahead? Growth ETFs to Play 

Weak hiring and rising jobless rates have San Francisco Fed President Mary Daly eyeing Fed rate cuts. If the Fed cuts rates soon, growth ETFs like RPG and IVW could benefit.

Growth ETFs Set New Records, Brush Off Tariff Headwinds

Growth ETFs like MGK, VUG, IWY, IUSG, and SPYG and others hit fresh highs as investors shrug off tariff threats and chase AI-fueled momentum.


Vanguard Admiral Funds - Vanguard S&P 500 Growth ETF

Still early innings

Overdone

Consolidation due before next leg up

Memory stocks have surged over the past year - is the run overdone or still early innings?

Current Price	$80.73
Prev Close	$78.96
Open	$79.75
Dividend Yield	N/A
50-Day Moving Average	$72.85
Beta	N/A
Avg. Volume	1.62M
PE Ratio	N/A

52-Week High	$80.81
52-Week Low	$57.98
Market Capitalization	N/A
EPS (Annual)	N/A
Price to Book	N/A
Revenue Per Employee	N/A

VOOG
Vanguard S&P 500 Growth ETF

Feed

News

Sentiment

Fundamentals

Info

Latest VOOG News

VOOGVanguard S&P 500 Growth ETF